Search

Your search keyword '"Olascoaga, Javier"' showing total 6 results
Start Over Author "Olascoaga, Javier" Publisher elsevier b.v.
6 results on '"Olascoaga, Javier"'

1. Clinical and therapeutic predictors of disease outcomes in AQP4-IgG+ neuromyelitis optica spectrum disorder

Author

Kunchok, Amy, Malpas, Charles, Nytrova, Petra, Havrdova, Eva Kubala, Alroughani, Raed, Terzi, Murat, Yamout, Bassem, Hor, Jyh Yung, Karabudak, Rana, Boz, Cavit, Ozakbas, Serkan, Olascoaga, Javier, Simo, Magdolna, Granella, Franco, Patti, Francesco, McCombe, Pamela, Csepany, Tunde, Singhal, Bhim, Bergamaschi, Roberto, Fragoso, Yara, Al-Harbi, Talal, Turkoglu, Recai, Lechner-Scott, Jeannette, Laureys, Guy, Oreja-Guevara, Celia, Pucci, Eugenio, Sola, Patrizia, Ferraro, Diana, Altintas, Ayse, Soysal, Aysun, Vucic, Steve, Grand'Maison, Francois, Izquierdo, Guillermo, Eichau, Sara, Lugaresi, Alessandra, Onofrj, Marco, Trojano, Maria, Marriott, Mark, Butzkueven, Helmut, Kister, Ilya, and Kalincik, Tomas

Published
2020
Full Text
View/download PDF

2. Incidence of pregnancy and disease-modifying therapy exposure trends in women with multiple sclerosis: A contemporary cohort study

Author

Nguyen, Ai-Lan, Havrdova, Eva Kubala, Horakova, Dana, Izquierdo, Guillermo, Kalincik, Tomas, van der Walt, Anneke, Terzi, Murat, Alroughani, Raed, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Boz, Cavit, Sola, Patrizia, Ferraro, Diana, Lugaresi, Alessandra, Lechner-Scott, Jeannette, Barnett, Michael, Grand'Maison, Francois, Grammond, Pierre, Ramo-Tello, Cristina, Turkoglu, Recai, McCombe, Pamela, Pucci, Eugenio, Trojano, Maria, Granella, Franco, Spitaleri, Daniele, Van Pesch, Vincent, Soysal, Aysun, Oreja-Guevara, Celia, Verheul, Freek, Vucic, Steve, Hodgkinson, Suzanne, Slee, Mark, Ampapa, Radek, Prevost, Julie, Menoyo, Jose Luis Sanchez, Skibina, Olga, Solaro, Claudio, Olascoaga, Javier, Shaw, Cameron, Madsen, Klaus Gregaard, Naidoo, Kerisha, Hyde, Robert, Butzkueven, Helmut, and Jokubaitis, Vilija

Published
2019
Full Text
View/download PDF

5. Reply to: Comment on Y.D. Fragoso et al.: “Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod” [Mult. Scler. Relat. Disord. (2017)]

Author

Fragoso, Yara Dadalti, Spelman, Tim, Boz, Cavit, Alroughani, Raed, Lugaresi, Alessandra, Vucic, Steve, Butzkueven, Helmut, Terzi, Murat, Havrdova, Eva, Horakova, Dana, Granella, Franco, Olascoaga, Javier, Menoyo, José Luis Sánchez, Pucci, Eugenio, Barnett, Michael, Brooks, Joseph Bruno B., and Haartsen, Jodi

Published
2018
Full Text
View/download PDF

6. Age gene expression and coexpression progressive signatures in peripheral blood leukocytes.

Author

Irizar, Haritz, Goñi, Joaquín, Alzualde, Ainhoa, Castillo-Triviño, Tamara, Olascoaga, Javier, Lopez de Munain, Adolfo, and Otaegui, David

Subjects
*LEUCOCYTES, *GENE expression, *CELLULAR aging, *IMMUNOSENESCENCE, *CELL growth, *LONGITUDINAL method
Abstract

Both cellular senescence and organismic aging are known to be dynamic processes that start early in life and progress constantly during the whole life of the individual. In this work, with the objective of identifying signatures of age-related progressive change at the transcriptomic level, we have performed a whole-genome gene expression analysis of peripheral blood leukocytes in a group of healthy individuals with ages ranging from 14 to 93 years. A set of genes with progressively changing gene expression (either increase or decrease with age) has been identified and contextualized in a coexpression network. A modularity analysis has been performed on this network and biological-term and pathway enrichment analyses have been used for biological interpretation of each module. In summary, the results of the present work reveal the existence of a transcriptomic component that shows progressive expression changes associated to age in peripheral blood leukocytes, highlighting both the dynamic nature of the process and the need to complement young vs. elder studies with longitudinal studies that include middle aged individuals. From the transcriptional point of view, immunosenescence seems to be occurring from a relatively early age, at least from the late 20s/early 30s, and the 49–56 year old age-range appears to be critical. In general, the genes that, according to our results, show progressive expression changes with aging are involved in pathogenic/cellular processes that have classically been linked to aging in humans: cancer, immune processes and cellular growth vs. maintenance. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results